diphenhydramine has been researched along with Mast Cell Activation Disease in 4 studies
Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.
antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mastocytosis is an accumulation of clonal mast cells within tissues, commonly caused by mutations in the KIT proto-oncogene." | 2.61 | Management of a neonate with diffuse cutaneous mastocytosis: Case report and literature review. ( Carter, MC; Diaz, LZ; Jenkinson, HA; Levy, ML; Lundgren, AD, 2019) |
| "Dyspareunia, vaginitis and dysfunctional uterine bleeding (DUB) are common problems which, despite their polygenicity, commonly appear idiopathic and treatment-refractory." | 1.51 | Successful mast-cell-targeted treatment of chronic dyspareunia, vaginitis, and dysfunctional uterine bleeding. ( Afrin, LB; Dempsey, TT; Dorff, SR; Rosenthal, LS, 2019) |
| "Continuous diphenhydramine infusion can provide promising outcomes following the failure of intermittent antihistamine dosing in patients with severe mast cell activation syndrome." | 1.46 | Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report. ( Ali, N; Boigon, M; Fidler, C; Ghani, A; Hamid, M; Jafri, SIM; Malik, F, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malik, F | 1 |
| Ali, N | 1 |
| Jafri, SIM | 1 |
| Ghani, A | 1 |
| Hamid, M | 1 |
| Boigon, M | 1 |
| Fidler, C | 1 |
| Jenkinson, HA | 1 |
| Lundgren, AD | 1 |
| Carter, MC | 1 |
| Diaz, LZ | 1 |
| Levy, ML | 1 |
| Afrin, LB | 1 |
| Dempsey, TT | 1 |
| Rosenthal, LS | 1 |
| Dorff, SR | 1 |
| Jacoby, BG | 1 |
| Wesley, RE | 1 |
1 review available for diphenhydramine and Mast Cell Activation Disease
| Article | Year |
|---|---|
Management of a neonate with diffuse cutaneous mastocytosis: Case report and literature review.
Topics: Cetirizine; Diphenhydramine; Drug Therapy, Combination; Gene Expression Regulation, Developmental; H | 2019 |
3 other studies available for diphenhydramine and Mast Cell Activation Disease
| Article | Year |
|---|---|
Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report.
Topics: Adolescent; Diphenhydramine; Female; Histamine H1 Antagonists; Humans; Imatinib Mesylate; Infusions, | 2017 |
Successful mast-cell-targeted treatment of chronic dyspareunia, vaginitis, and dysfunctional uterine bleeding.
Topics: Administration, Topical; Adult; Anti-Allergic Agents; Anti-Asthmatic Agents; Cromolyn Sodium; Diphen | 2019 |
Painful orbital inflammatory lesions and mastocytosis.
Topics: Adolescent; Biopsy; Cimetidine; Clemastine; Combined Modality Therapy; Diphenhydramine; Drug Therapy | 1987 |